by | Jul 15, 2020 | Rothlauf, Paul, Whelan, Sean
— Background: Recombinant vesicular stomatitis virus (VSV) has successfully been used to create a vaccine for Ebola virus that is currently on the market. Previously, Professor Sean Whelan and colleagues have exploited the VSV platform to create similar vectors for both SARS and MERS.
Technology: The…
by | Jun 26, 2020 | Ellebedy, Ali
— Species: Human
Target: SARS-CoV-2 nucleocapsid protein
Applications:
Description: Two recombinant fully human monoclonal antibodies that recognize SARS-CoV-2 spike protein (data below).
Related Web Links: Ellebedy Profile; Ellebedy Lab
by Jennifer | Jun 25, 2020 | Diamond, Michael, Hassan, Ahmed
— Technology Description
Researchers at Washington University in St. Louis have developed a method to sensitize commercially available laboratory mice to SARS-CoV-2 infection. SARS-CoV-2 is the cause of the coronavirus disease 2019 (COVID-19) pandemic that has had severe morbidity and mortality impa…
by | Jun 4, 2020 | Curiel, David, Diamond, Michael, Dmitriev, Igor, Hassan, Ahmed
— Technology Description
Researchers at Washington University in St. Louis have developed a chimpanzee adenovirus-based vaccine for COVID-19. COVID-19, the clinical syndrome caused by SARS-CoV-2 infection, has had extensive morbidity and mortality impacts and destabilized society. There is an urg…
by | Feb 10, 2020 | Brien, James, Diamond, Michael, Shrestha, Bimmi, Sukupolvi, Soila
— Description: Monoclonal antibodies against Dengue virus E proteins. These mAbs are generated in mouse against different Dengue viruses and have been shown, by functional assays, to neutralize infection of the individual Dengue serotypes.
Target: Dengue Virus
Notes: Contact for more info.
Publicat…